Continuation study in patients who have completed a previous oncology study with olaparib and who are considered by the investigator to clinically benefit from continuing treatment. ROSY-O
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ASTRAZENECA AB
- Phase: III
- Execution start: 21/06/2021
- End of execution: 30/09/2030
- IP: ENCARNA GONZALEZ FLORES